Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16742094 | 0.88 | TDP1 (0.66) | TDP1ALDH1A1POLBAPEX1RECQL | |
| SCHEMBL7798232 | 0.84 | TDP1 (0.42) | TDP1ALDH1A1KDM4EGAAHSD17B10 | |
| SCHEMBL7788801 | 0.83 | TDP1 (0.41) | TDP1ALDH1A1POLBAPEX1RECQL | |
| SCHEMBL7270775 | 0.79 | HPGD (0.42) | MAPT | |
| SCHEMBL8131639 | 0.78 | TDP1 (0.56) | TDP1ALDH1A1POLBAPEX1RECQL | |
| SCHEMBL8690783 | 0.77 | TDP1 (1.00) | TDP1ALDH1A1POLBAPEX1RECQL | |
| SCHEMBL22662965 | 0.77 | TDP1 (0.55) | TDP1ALDH1A1POLBAPEX1RECQL | |
| SCHEMBL7795628 | 0.76 | CXCR2 (0.39) | TDP1PTGS2 | |
| SCHEMBL16742113 | 0.74 | TDP1 (0.66) | TDP1ALDH1A1POLBAPEX1RECQL | |
| SCHEMBL8131638 | 0.72 | TDP1 (0.56) | TDP1ALDH1A1POLBAPEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | TDP1 4495/4885ALDH1A1 2598/4885POLB 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.